Design, synthesis and anti-hepatic fibrosis activity of novel diphenyl vitamin D receptor agonists
作者:Kai Xing、Yue Wu、Fei Gao、Yupeng Dai、Chun Guan、Yu Tong、Yi Gao、Cong Wang、Can Zhang
DOI:10.1016/j.ejmech.2023.115596
日期:2023.10
vitamin D receptor (VDR) has been identified as an effective target for hepatic fibrosis, reducing ECM by inhibiting hepatic stellate cell (HSC) activation. Here, a series of novel diphenyl VDR agonists have been rationally designed and synthesized. Among these, compounds 15b, 16i, and 28m showed better transcriptional activity compared to sw-22, which was previously reported to be a potent non-secosteroidal
肝纤维化是由于细胞外基质(ECM)过度沉积导致肝功能损害而对人类健康构成重大威胁。配体激活的维生素 D受体 (VDR) 已被确定为肝纤维化的有效靶标,通过抑制肝星状细胞(HSC) 激活来减少 ECM。在此,合理设计并合成了一系列新型二苯基VDR激动剂。其中,与sw-22相比,化合物15b、 16i和28m显示出更好的转录活性,而 sw-22 之前被报道为有效的非分泌类固醇 VDR 调节剂。此外,这些化合物在体外表现出出色的抑制胶原蛋白沉积的功效。在CCl 4诱导和胆管结扎诱导的肝纤维化模型中,通过超声成像和组织学检查,化合物16i显示出最显着的治疗效果。此外,16i能够通过降低纤维化基因和血清肝功能指标的表达水平来修复肝组织,而不会引起小鼠高钙血症。总之,化合物16i是一种有效的VDR激动剂,在体外和体内均具有显着的抗肝纤维化作用。